Citizens Jmp Cuts Structure Therapeutics (NASDAQ:GPCR) Price Target to $110.00

Structure Therapeutics (NASDAQ:GPCR) had its target price dropped by equities research analysts at Citizens Jmp from $113.00 to $110.00 in a report released on Friday,Benzinga reports. The firm currently has a “market outperform” rating on the stock. Citizens Jmp’s price target suggests a potential upside of 111.80% from the stock’s current price.

GPCR has been the subject of several other reports. Canaccord Genuity Group set a $111.00 price target on shares of Structure Therapeutics in a report on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a report on Friday, July 17th. Wall Street Zen upgraded Structure Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. Citigroup reaffirmed a “market outperform” rating on shares of Structure Therapeutics in a report on Friday. Finally, HC Wainwright dropped their target price on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research report on Thursday, June 11th. Three analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $111.18.

Structure Therapeutics Stock Performance

Shares of Structure Therapeutics stock traded down $0.68 during midday trading on Friday, hitting $51.94. 100,729 shares of the company traded hands, compared to its average volume of 892,462. The stock has a market cap of $3.69 billion, a price-to-earnings ratio of -59.95 and a beta of -1.43. The firm’s fifty day moving average price is $47.36 and its 200-day moving average price is $54.20. Structure Therapeutics has a 12 month low of $15.86 and a 12 month high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). Equities research analysts forecast that Structure Therapeutics will post -1.64 earnings per share for the current year.

Hedge Funds Weigh In On Structure Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in GPCR. Sterling Capital Management LLC acquired a new position in shares of Structure Therapeutics during the first quarter worth $28,000. State of Wyoming bought a new stake in shares of Structure Therapeutics in the second quarter worth $28,000. CWM LLC increased its holdings in Structure Therapeutics by 35.2% in the fourth quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after purchasing an additional 125 shares during the period. Assetmark Inc. increased its holdings in Structure Therapeutics by 21.4% in the first quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock valued at $123,000 after purchasing an additional 449 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey bought a new position in Structure Therapeutics during the 4th quarter worth $127,000. 91.78% of the stock is currently owned by institutional investors and hedge funds.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.